We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Vascepa Exclusivity Ruling Spells More Regulatory Woe for Amarin
Vascepa Exclusivity Ruling Spells More Regulatory Woe for Amarin
Amarin has received more bad news from the FDA, which granted its prescription fish oil pill just three years of exclusivity instead of five — a decision limiting market power for the drug as it struggles to win an expanded indication.